These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24801282)

  • 1. Covalent conjugation of a peptide triazole to HIV-1 gp120 enables intramolecular binding site occupancy.
    Emileh A; Duffy C; Holmes AP; Rosemary Bastian A; Aneja R; Tuzer F; Rajagopal S; Li H; Abrams CF; Chaiken IM
    Biochemistry; 2014 Jun; 53(21):3403-14. PubMed ID: 24801282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.
    Emileh A; Tuzer F; Yeh H; Umashankara M; Moreira DR; Lalonde JM; Bewley CA; Abrams CF; Chaiken IM
    Biochemistry; 2013 Apr; 52(13):2245-61. PubMed ID: 23470147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators.
    Zhang S; Holmes AP; Dick A; Rashad AA; Enríquez Rodríguez L; Canziani GA; Root MJ; Chaiken IM
    Retrovirology; 2021 Oct; 18(1):31. PubMed ID: 34627310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664.
    Acharya K; Rashad AA; Moraca F; Klasse PJ; Moore JP; Abrams C; Chaiken I
    Proteins; 2017 May; 85(5):843-851. PubMed ID: 28056499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism.
    Tuzer F; Madani N; Kamanna K; Zentner I; LaLonde J; Holmes A; Upton E; Rajagopal S; McFadden K; Contarino M; Sodroski J; Chaiken I
    Proteins; 2013 Feb; 81(2):271-90. PubMed ID: 23011758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120.
    Aneja R; Rashad AA; Li H; Kalyana Sundaram RV; Duffy C; Bailey LD; Chaiken I
    J Med Chem; 2015 May; 58(9):3843-58. PubMed ID: 25860784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.
    Umashankara M; McFadden K; Zentner I; Schön A; Rajagopal S; Tuzer F; Kuriakose SA; Contarino M; Lalonde J; Freire E; Chaiken I
    ChemMedChem; 2010 Nov; 5(11):1871-9. PubMed ID: 20677318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.
    Gift SK; Zentner IJ; Schön A; McFadden K; Umashankara M; Rajagopal S; Contarino M; Duffy C; Courter JR; Zhang MY; Gershoni JM; Cocklin S; Dimitrov DS; Smith AB; Freire E; Chaiken IM
    Biochemistry; 2011 Apr; 50(14):2756-68. PubMed ID: 21351734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120.
    Gopi H; Cocklin S; Pirrone V; McFadden K; Tuzer F; Zentner I; Ajith S; Baxter S; Jawanda N; Krebs FC; Chaiken IM
    J Mol Recognit; 2009; 22(2):169-74. PubMed ID: 18498083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4.
    Zhang W; Godillot AP; Wyatt R; Sodroski J; Chaiken I
    Biochemistry; 2001 Feb; 40(6):1662-70. PubMed ID: 11327825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.
    Rosemary Bastian A; Nangarlia A; Bailey LD; Holmes A; Kalyana Sundaram RV; Ang C; Moreira DR; Freedman K; Duffy C; Contarino M; Abrams C; Root M; Chaiken I
    J Biol Chem; 2015 Jan; 290(1):529-43. PubMed ID: 25371202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies.
    Kaplan G; Roitburd-Berman A; Lewis GK; Gershoni JM
    J Virol; 2016 May; 90(9):4481-4493. PubMed ID: 26889042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
    Dey B; Del Castillo CS; Berger EA
    J Virol; 2003 Mar; 77(5):2859-65. PubMed ID: 12584309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein.
    Kassa A; Dey AK; Sarkar P; Labranche C; Go EP; Clark DF; Sun Y; Nandi A; Hartog K; Desaire H; Montefiori D; Carfi A; Srivastava IK; Barnett SW
    PLoS One; 2013; 8(10):e76139. PubMed ID: 24146829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular mechanism of two coreceptor binding site antibodies X5 and 17b neutralizing HIV-1: Insights from molecular dynamics simulation.
    Zhang Y; Guo J; Huang L; Tian J; Yao X; Liu H
    Chem Biol Drug Des; 2018 Jul; 92(1):1357-1365. PubMed ID: 29624884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
    J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.
    Gopi H; Umashankara M; Pirrone V; LaLonde J; Madani N; Tuzer F; Baxter S; Zentner I; Cocklin S; Jawanda N; Miller SR; Schön A; Klein JC; Freire E; Krebs FC; Smith AB; Sodroski J; Chaiken I
    J Med Chem; 2008 May; 51(9):2638-47. PubMed ID: 18402432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
    Zhang W; Canziani G; Plugariu C; Wyatt R; Sodroski J; Sweet R; Kwong P; Hendrickson W; Chaiken I
    Biochemistry; 1999 Jul; 38(29):9405-16. PubMed ID: 10413516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disulfide Sensitivity in the Env Protein Underlies Lytic Inactivation of HIV-1 by Peptide Triazole Thiols.
    Bailey LD; Kalyana Sundaram RV; Li H; Duffy C; Aneja R; Rosemary Bastian A; Holmes AP; Kamanna K; Rashad AA; Chaiken I
    ACS Chem Biol; 2015 Dec; 10(12):2861-73. PubMed ID: 26458166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.